Tag Archives: aeri

Aerie Pharma Surges On Glaucoma Drug Trial Results

Shares of biotech Aerie Pharmaceuticals (AERI) vaulted as much as 85% Thursday and got a passel of price target increases after the company announced late Wednesday that its glaucoma drug had succeeded in a late-stage clinical trial. Aerie said that its eye drop Rhopressa had succeeded in lowering intra-ocular pressure in sufferers from glaucoma and ocular hypertension. Its goal was to show that a once-daily dose of Rhopressa was non-inferior to

Aerie Soars, Avalanche Crashes On Eye Drug News

Two biotechs treating eye diseases were making huge moves in opposite directions Tuesday morning after equally different drug news came out late Monday. Aerie Pharmaceuticals (AERI) stock soared more than 50%, near 20, and the company got an upgrade after it said that the FDA had agreed to a redesign of a clinical trial of beleaguered glaucoma treatment Rhopressa. Aerie’s stock tumbled 64% on April 24, near 13, after a phase-three trial, called

Aerie Pharmaceuticals Rockets After Drug Trial News

Aerie Pharmaceuticals (AERI) stock rocketed as much as 41% in the stock market today after the company, which develops therapies for treating patients with eye diseases, reported upbeat phase 2b trial results for its experimental glaucoma drug Roclatan. Roclatan is an eyedrop treatment that can be administered on a once-daily basis. It is a combination of Aerie’s Rhopressa (phase 3 trial triple-action glaucoma drug candidate) and latanoprost, a